FHA
AERI

Flagship Harbor Advisors’s Aerie Pharmaceuticals AERI Stock Holding History

Flagship Harbor Advisors’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-115
Closed -$1K – 2223
2020
Q2 		$1K Buy
+115
New +$1.7K ﹤0.01% 1982

Other funds holding AERI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return

Flagship Harbor Advisors's AERI Position: Q3 2020 in Review

Flagship Harbor Advisors sold out of Aerie Pharmaceuticals (AERI) in Q3 2020, closing a stake of 115 shares — an estimated $1K sold.

Flagship Harbor Advisors first reported a position in AERI in Q2 2020 and held it in 1 quarter. The position peaked at $1K in Q2 2020. 148 funds tracked by Wall St. Rank hold AERI as of Q3 2020.

  • Flagship Harbor Advisors reported no remaining Aerie Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Flagship Harbor Advisors sold 115 Aerie Pharmaceuticals shares in Q3 2020, an estimated $1K.
  • Flagship Harbor Advisors first reported a position in Aerie Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Flagship Harbor Advisors's Aerie Pharmaceuticals position peaked at $1K in Q2 2020.
  • 148 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2020.

Based on Flagship Harbor Advisors's 13F filing for Q3 2020, filed 13 Oct 2020.